168 related articles for article (PubMed ID: 8704064)
1. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans.
Pietrowsky R; Strüben C; Mölle M; Fehm HL; Born J
Biol Psychiatry; 1996 Mar; 39(5):332-40. PubMed ID: 8704064
[TBL] [Abstract][Full Text] [Related]
2. Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons.
Schreiber H; Stolz-Born G; Pietrowsky R; Kornhuber HH; Fehm HL; Born J
Biol Psychiatry; 1995 May; 37(10):702-12. PubMed ID: 7640325
[TBL] [Abstract][Full Text] [Related]
3. Effects of vasopressin on event-related potential indicators of cognitive stimulus processing in young and old humans.
Dodt C; Pietrowsky R; Sewing A; Zabel A; Fehm HL; Born J
J Gerontol; 1994 Jul; 49(4):M183-8. PubMed ID: 8014393
[TBL] [Abstract][Full Text] [Related]
4. The influence of a vasopressin-analogue (DGAVP) on event-related potentials in a stimulus-mismatch paradigm.
Pietrowsky R; Born J; Fehm-Wolfsdorf G; Fehm HL
Biol Psychol; 1989 Jun; 28(3):239-50. PubMed ID: 2686760
[TBL] [Abstract][Full Text] [Related]
5. Effect of intranasal arginine vasopressin on human headache.
Yang J; Lu L; Wang HC; Zhan HQ; Hai GF; Pan YJ; Lv QQ; Wang DX; Wu YQ; Li RR; Xue L; Wang XH; Deng XM; Liu XF; Qian YN; Deng ZK; Zhang ZJ; Zhan XH; Zhou XJ; Wang GL; Zhai JX; Wang JC
Peptides; 2012 Nov; 38(1):100-4. PubMed ID: 22963731
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study.
Christrup LL; Foster D; Popper LD; Troen T; Upton R
Clin Ther; 2008 Mar; 30(3):469-81. PubMed ID: 18405786
[TBL] [Abstract][Full Text] [Related]
7. Flunitrazepam-induced changes in neurophysiological, behavioural, and subjective measures used to assess sedation.
Lucchesi LM; Pompéia S; Manzano GM; Kohn AF; Galduroz JC; Bueno OF; Tufik S
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):525-33. PubMed ID: 12691789
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin and oxytocin do not influence early sensory processing but affect mood and activation in man.
Pietrowsky R; Braun D; Fehm HL; Pauschinger P; Born J
Peptides; 1991; 12(6):1385-91. PubMed ID: 1815225
[TBL] [Abstract][Full Text] [Related]
9. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin.
Pietrowsky R; Thiemann A; Kern W; Fehm HL; Born J
Psychoneuroendocrinology; 1996 Aug; 21(6):559-72. PubMed ID: 8983091
[TBL] [Abstract][Full Text] [Related]
10. Caffeine effects on ERPs and performance in an auditory Go/NoGo task.
Barry RJ; Johnstone SJ; Clarke AR; Rushby JA; Brown CR; McKenzie DN
Clin Neurophysiol; 2007 Dec; 118(12):2692-9. PubMed ID: 17905651
[TBL] [Abstract][Full Text] [Related]
11. Arginine vasopressin prevents amyloid beta protein-induced impairment of long-term potentiation in rat hippocampus in vivo.
Jing W; Guo F; Cheng L; Zhang JF; Qi JS
Neurosci Lett; 2009 Feb; 450(3):306-10. PubMed ID: 19059464
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin attenuates TNF-mediated inflammation in the rat cremaster microcirculation.
McMahon PJ; Proctor KG
J Trauma; 2009 Sep; 67(3):461-73; discussion 473-5. PubMed ID: 19741386
[TBL] [Abstract][Full Text] [Related]
13. Repetitive intranasal administration of cholecystokinin potentiates its central nervous effects.
Denecke H; Meyer F; Feldkamp J; Fritzen R; Pietrowsky R
Physiol Behav; 2004 Oct; 83(1):39-45. PubMed ID: 15501489
[TBL] [Abstract][Full Text] [Related]
14. The influence of stimulus deviance and novelty on the P300 and novelty P3.
Goldstein A; Spencer KM; Donchin E
Psychophysiology; 2002 Nov; 39(6):781-90. PubMed ID: 12462506
[TBL] [Abstract][Full Text] [Related]
15. Sources of auditory selective attention and the effects of methylphenidate in children with attention-deficit/hyperactivity disorder.
Kemner C; Jonkman LM; Kenemans JL; Böcker KB; Verbaten MN; Van Engeland H
Biol Psychiatry; 2004 Apr; 55(7):776-8. PubMed ID: 15039009
[TBL] [Abstract][Full Text] [Related]
16. Brain potentials and attention after acute and subchronic intranasal administration ofACTH 4-10 and desacetyl-alpha-MSH in humans.
Smolnik R; Mölle M; Fehm HL; Born J
Neuroendocrinology; 1999 Jul; 70(1):63-72. PubMed ID: 10420094
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory.
van Laar MW; Volkerts ER; Verbaten MN; Trooster S; van Megen HJ; Kenemans JL
Psychopharmacology (Berl); 2002 Aug; 162(4):351-63. PubMed ID: 12172688
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of endotoxaemia on pressor and vasoconstrictor actions of angiotensin II and arginine vasopressin in conscious rats.
Tarpey SB; Bennett T; Randall MD; Gardiner SM
Br J Pharmacol; 1998 Apr; 123(7):1367-74. PubMed ID: 9579732
[TBL] [Abstract][Full Text] [Related]
19. Effects of cortisol on the laterality of the neural correlates of episodic memory.
Alhaj HA; Massey AE; McAllister-Williams RH
J Psychiatr Res; 2008 Oct; 42(12):971-81. PubMed ID: 18187154
[TBL] [Abstract][Full Text] [Related]
20. Salivary vasopressin increases following intranasal oxytocin administration.
Weisman O; Schneiderman I; Zagoory-Sharon O; Feldman R
Peptides; 2013 Feb; 40():99-103. PubMed ID: 23246527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
